

Absolute Omega ES



Clinical Applications

- Affects the Production of Arachidonic Acid-Derived Eicosanoids*
- Supports Cardiovascular Health*
- Helps the Body Generate Specialized Pro-Resolving Lipid Mediators, Such as Resolvins and Protectins*
- Supports Healthy Mental Functioning*
- Supports Healthy Glucose and Insulin Metabolism*

Absolute Omega ES are concentrated fish oils that provide 600-900 mg of EPA and DHA and are delivered in a small, fish-gelatin-based softgel. EPA and DHA from fish oil promote wellness by supporting cardiovascular health, cytokine balance, joint health, and brain and nervous system function.

All Absolute Health Formulas Meet or Exceed cGMP Quality Standards

Discussion

Source and Processing The omega-3 concentrate used in Absolute Health's Absolute Omega line of fish oils is exclusively sourced from US-caught fish, namely certified sustainable wild Alaskan walleye pollock and Pacific whiting obtained from the cold, clear waters off Alaska. Freshly caught fish are processed within hours to make quick-frozen fish fillets. The result is exceptionally fresh raw fish oil. To achieve the level of quality found in Absolute Omega fish oils, a series of critical steps are undertaken: (1) raw fish oil triglycerides are broken down into ethyl esters; (2) EPA and DHA are separated from other fats and concentrated through flash distillation; (3) cold extraction further concentrates the oil, resulting in up to 85% omega-3; (4) molecular distillation removes fishy odor and taste, resulting in extremely fresh oil; (5) PCBs, chlorinated organic pollutants, and toxic heavy metals are removed through filtration; and (6) high purity products are packaged in 190 kg drums or 900 kg totes under inert gas.

GRAS-Certified Enteric Coating Absolute Omega fish oils employ a fish-gelatin—not a bovine-gelatin—softgel that is enteric-coated and GRAS-certified to further guarantee quality. The enteric coating helps ensure that the fish oils reach the small intestine before being metabolized, resulting in better delivery of actives to the intestines for absorption. This delivery may also reduce the occurrence of a fishy aftertaste.

Ethyl Ester Form Despite aggressive marketing claims to the contrary, a recent publication by Oelrich et al found that no significant difference in the effect on serum triglycerides was detected in patients taking triglyceride (TG) or ethyl ester forms of omega-3 supplements.¹ In the study, three fish oil supplementation forms were examined. The active therapy was 4 g/day of combined EPA and DHA provided as: a 90% TG formulation, a 60% TG formulation, or ethyl esters (i.e., 0% TG). In addition to the main finding, researchers also noted that the omega-3 fish oils provided in the ethyl ester form tended to have less impact on increasing LDL-cholesterol levels compared to the omega-3 fish oils delivered in the triglyceride form.

Health Benefits of EPA/DHA Research and studies have shown that omega-3 fatty acids antagonize arachidonic acid-induced eicosanoid formation; help generate resolvins and protectins to aid the body's "cleanup" response to the arachidonic acid cascade; promote neurological health and mental functioning; and promote cardiovascular health, a balanced immune response, and healthy glucose and insulin metabolism.²⁻¹⁴ Research suggests that it takes 2 g/day of DHA supplementation over a period of a month to saturate the plasma and three to six months of supplementation to saturate the tissues.¹⁵ Concentrations of DHA increased in breast milk within less than a week of supplementation.¹⁵

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Absolute Health
7350 SW 60th Ave., Suite 2
Ocala, FL 34476
www.AbsoluteHealthOcala.com

Absolute Omega ES



Supplement Facts

Serving Size: 2 Softgels
Servings Per Container: 60

	Amount Per Serving	%Daily Value
Calories	20	
Calories from Fat	20	
Total Fat	2 g	3%
Fish Oil Concentrate	2.8 g	**
Total Omega-3 Fatty Acids	1.82 g	**
EPA (eicosapentaenoic acid)	900 mg	**
DHA (docosahexaenoic acid)	660 mg	**

† Percent Daily Values are based on a 2,000-calorie diet. ** Daily Value not established.

Other Ingredients: Softgel (tilapia fish gelatin, vegetable glycerin, and purified water), GRAS enteric coating (purified water, ethylcellulose, sodium alginate, ammonium hydroxide, medium-chain triglycerides, oleic acid, and vegetable stearic acid), and mixed natural tocopherols.

Contains: Fish (Alaska pollock, Pacific whiting [sources of fish oil], tilapia [source of fish gelatin]) from certified sustainable sources.

Directions

Take one or two softgels one to three times daily, or as directed by your healthcare practitioner.

Consult your healthcare provider prior to use. Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare provider. Do not use if tamper seal is damaged.

Does Not Contain

Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.



References

- Oelrich B, Dewell A, Gardner CD. Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults. *Nutr Metab Cardiovasc Dis.* 2011 Sep 15. Epub ahead of print. [PMID: 21924882]
- Storey A, McArdle F, Friedmann PS, et al. Eicosapentaenoic acid and docosahexaenoic acid reduce UVB- and TNF alpha-induced IL-8 secretion in keratinocytes and UVB-induced IL-8 in fibroblasts. *J Invest Dermatol.* 2005 Jan;124(1):248-55. [PMID: 15654981]
- Kim YJ, Kim HJ, No JK, et al. Anti-inflammatory action of dietary fish oil and calorie restriction. *Life Sci.* 2006 Apr 18;78(21):2523-32. [PMID: 16438990]
- Maroon JC, Bost JW. Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. *Surg Neurol.* 2006 Apr;65(4):326-31. [PMID: 16531187]
- Weylandt KH, Chiu CY, Gomolka B, et al. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvins and protectin formation. *Prostaglandins Other Lipid Mediat.* 2012 Mar;97(3-4):73-82. [PMID: 22326554]
- Kremmyda LS, Tvrzicka E, Stankova B, et al. Fatty acids as biocompounds: their role in human metabolism, health and disease: a review. part 2: fatty acid physiological roles and applications in human health and disease. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2011 Sep;155(3):195-218. [PMID: 22286806]
- Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. *Br J Psychiatry.* 2006 Jan;188:46-50. [PMID: 16388069]
- Kankaanpaa P, Sutas Y, Salminen S, et al. Dietary fatty acids and allergy. *Ann Med.* 1999 Aug;31(4):282-87. [PMID: 10480759]
- Ebbesson SO, Risica PM, Ebbesson LO, et al. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. *Int J Circumpolar Health.* 2005 Sep;64(4):396-408. [PMID:16277123]
- Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. *J Am Diet Assoc.* 2005 Mar;105(3):428-40. [PMID:15746832]
- Weitz D, Weintraub H, Fisher E, et al. Fish oil for the treatment of cardiovascular disease. *Cardiol Rev.* 2010 Sep-Oct;18(5):258-63. [PMID: 20699674]
- Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. *Am J Cardiol.* 2006 Aug 21;98(4A):3i-18i. [PMID: 16919512]
- Sasaki J, Yokoyama M, Matsuzaki M, et al. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). *J Atheroscler Thromb.* 2012;19(2):194-204. [PMID: 22186099]
- Zhang J, Wang C, Li L, et al. Inclusion of Atlantic salmon in the Chinese diet reduces cardiovascular disease risk markers in dyslipidemic adult men. *Nutr Res.* 2010 Jul;30(7):447-54. [PMID: 20797476]
- Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. *Am J Clin Nutr.* 2006 Jun;83(6 Suppl):1467S-1476S. Review. [PMID: 16841856]

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.